HONG KONG, Nov. 1, 2016
HONG KONG, Nov. 1, 2016 /PRNewswire/ -- In the United States alone, an estimated 15 million fractures occurs annually, including 1.6 million hospital admissions for traumatic fractures and 2 million osteoporotic fractures, costing over 60 billion dollars and calling for 1.6 million bone grafts each year; a growing demand for bone grafts is similarly observed worldwide. Bone is the second most commonly implanted material in the human body, after blood transfusion. The science of bone grafts in nonunion and bone loss have been established and refined, and new methods of bone graft extraction that limits pain and complications for these treatments should be determined, developed and implemented for the minimally invasive treatment advantages. A passive and effortless percutaneous method providing full control and precision for the endeavor would be supreme.
A "Bone Graft" is the basic ingredient and the basis of almost every major reconstructions for many orthopedic and spinal disorders which include deformities, degeneration, fractures and damages. Degenerative Disc Disease (DDD) commonly known as 'slipped disc', scoliosis, spondylolisthesis, spinal stenosis, and vertebral fractures all require a spinal fusion treatment using a "Bone Graft". According to the WHO Low Back Pain (LBC) is the number 1 cause of disability worldwide, and together with the treatments for severe neck pain, nonunion fractures of long bones, cranial maxillofacial fractures commonly consequent to automobile accidents and so on, they all firstly require a "Bone Graft" to repair the patient. Without a "Bone Graft", none of all these conditions can be suitably treated. The increased prevalence of spinal fusion surgery alone has created an industry focus on bone graft alternatives. While autologous bone graft, also known as autograft - the patient's own solid living bone tissue usually extracted from the hips remains the gold standard, but the pain and complications from extracting autologous bone graft, the problems with open surgery extraction drives the endless search for a reliable and safe bone graft substitute product. Many approaches are used in the repair of skeletal defects in reconstructive orthopedic surgery, and bone grafting is involved in virtually every procedure. Autografting (live bone extracted from the patient) remains the gold standard for replacing bone loss. Moreover most alternatives, including bone bank which bear contamination, artificial discs and stem cell products are expensive and mostly not compatible nor validated by Evidence based medicine EBM, thus being scarcely recommendable for clinical use. The search for alternative biomaterials for a bone graft continues.
This new surgical tool holds the United States Patent Number: 8920423 December 30, 2014 by Inventor : Dr. Benjamino Kah Hung Lee. It was first conceived, initiated and collaborated with The Government of the HKSAR (supported via The Hong Kong Productivity Council), and was presented at The Hong Kong Hospital Authority at their Annual Convention on 7th May, 2014.
After initial tests on animal bone, currently top USA scientists and surgeons at Barrow Neurological Institute in Phoenix, Arizona in the United States are preparing to conduct a Biomechanical Study to translate and introduce this surgical tool into the medical industry for clinical use. (Barrow Neurological Institute is the world's largest neurological disease treatment and research institution, and is consistently ranked as one of the best neurosurgical training centers in the United States). This new surgical tool is not available from any manufacturers and offers many new advantages which are equally applicable in many fields of medicine including for the spine and also for many other procedures; orthopedic surgery, spinal surgery, plastic surgery, cranial maxillofacial surgery, dentistry and dental implantology. A growing market for an aging population. Currently we are ready to manufacture the tool and a Gant Chart scheduled for the production process which will require 15-18 months to complete. We have two large hospitals in China interested to work together with us in using the surgical tool we developed for live bone extraction. One hospital group has orthopedic hospitals in Guangzhou and Wuhan. The second one is in Dalian port in Liaoning Province. All these 3 cities are important healthcare centers with enormous popularity with Chinese patients. While orthopedic surgeries, including spinal fusion and non-union fractures as well a host of degenerative bone ailments are currently being treated, their standards and quality of care and recovery has much room for improvement. Both groups are very excited about the potential of introducing new tools and procedures into China. We were also told that the demand for re-constructive surgery, dental implants has grown rapidly in recent years due to aging population. The China hospitals also explained that since this is a virgin territory without competition, it is possible to set up a "separate foundation specifically categorized for this tool and its novelty technique" to look into various limitless applications of this proven surgical percutaneous procedure for the direct transfer of bodily tissues and to popularize it in China for the beneficial sake of patients among the Chinese physicians and orthopedic surgeons, especially for how exactly to get a piece of live bone with effortless ease, remarkable expediency to save operation theatre time, and minimal discomfort, minimizing the risks of complications, reduce blood loss and reduce pain for an uneventful recovery.
The level of interest is for knowing that if this percutaneous approach can be installed, then ALL of the currently available known approaches for the reconstructions would bear far greater risks of complications overall, in addition to their greater time and costs involved, nevertheless.
In view of this, it is for certain that all the efforts of all persons interested to be pioneers in this medical field by joining in with our scientific team for collaborating with more biomechanical studies, beginning in USA and China will be immortalized, and to publish scientific documents under their names.
For further information and technical specifications, FDA details, engineering details, about this new orthopedic instrument, please contact: Dr. Benjamino Lee at firstname.lastname@example.org or please feel free to call Tel : 852-2808-4768 for press information.
For scientific information and the biomechanical study details, with potential interest to join our scientific team for biomechanical study side, please contact:
Dr. Brian P. Kelly phD, Director of Spine Biomechanics Laboratory
Barrow Neurological Institute, Department of Neurosurgery,
350 West Thomas Rd, Phoenix, Arizona, United States.
For investors who are interested in equity side, please contact our company with the IPR, and welcome to contact our CEO Dr. Ting Ho at QiBiotech Company for funding opportunity and business discussions.
QIBIOTECH COMPANY LIMITED
Room 510, 5th Floor, K. Wah Centre, 191 Java Road, North Point, Hong Kong.
Email:email@example.com Tel: +852 2765 8500 Fax: +852 2765 8555
This content was issued through the press release distribution service at Newswire.com. For more info visit: http://www.newswire.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/hkjdc-limited-announces-new-biomechanical-technology-invention-from-hong-kong-for-orthopedic-medicine-300354798.html
SOURCE HKJDC LimitedPR Newswire
Last updated on: 01/11/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.